Zobrazeno 1 - 10
of 204
pro vyhledávání: '"ALK-TKI"'
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
Liquid biopsies including pleural fluid or plasma are commonly applied for patients with advanced non-small cell lung cancer (NSCLC) and pleural effusion (PE) to guide the treatment. ALK-TKIs are the first options for patients with ALK-positive mutat
Externí odkaz:
https://doaj.org/article/cb72cb448c2f4df9aea7e3b2d6dc5ca1
Publikováno v:
Heliyon, Vol 10, Iss 11, Pp e32030- (2024)
Anaplastic lymphoma kinase (ALK) inhibitors are the recommended treatment of ALK-rearranged non-small cell lung cancer but are prone to eventual drug resistance.Herein we report a 45-year-old Asian woman diagnosed with EML4-ALK rearranged lung adenoc
Externí odkaz:
https://doaj.org/article/e04ca6bcd5b146f4a74a1bdef3846954
Publikováno v:
Lung Cancer: Targets and Therapy, Vol Volume 15, Pp 19-27 (2024)
Alexandria TM Lee,1 Sai-Hong Ignatius Ou1,2 1University of California Irvine School of Medicine, Department of Medicine, Orange, CA, USA; 2Chao Family Comprehensive Cancer Center, Orange, CA, USACorrespondence: Sai-Hong Ignatius Ou, Division of Hemat
Externí odkaz:
https://doaj.org/article/2546c96c26c048d3bbe7c62697e7dedb
Publikováno v:
Biomedicines, Vol 12, Iss 10, p 2308 (2024)
Lung cancer is the leading cause of cancer-related morbidity and mortality. The median survival time for patients with advanced non-small-cell lung cancer before the era of molecular-based personalized treatment was 7.9 months. The discovery of predi
Externí odkaz:
https://doaj.org/article/8252cef8f2c74b5095f3f33a30be9040
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
In patients with advanced lung adenocarcinoma (LADC) harboring the echinoderm microtubule-associated protein-like 4 (EML4) -anaplastic lymphoma kinase (ALK) rearrangement, targeted therapy typically demonstrates superior efficacy as an initial treatm
Externí odkaz:
https://doaj.org/article/7eacfcd31c234eb0821b614340d8d19c
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
Anaplastic lymphoma kinase gene (ALK) rearrangement is present in only approximately 5% of non-small cell lung cancers (NSCLCs) and is scarce in LCNEC patients. The conventional first-line treatment options are chemotherapy combined with immunotherap
Externí odkaz:
https://doaj.org/article/144b64a9358f4818a983073cf4c0a5b2
Autor:
DING Ning, ZHOU Jiebai
Publikováno v:
陆军军医大学学报, Vol 44, Iss 24, Pp 2493-2499 (2022)
Objective To compare and investigate the molecular profiles in acquired resistance-associated genetic alterations of second-generation anaplastic lymphoma kinase-tyrosine kinase inhibitors (ALK-TKIs) in order to provide evidence for the management of
Externí odkaz:
https://doaj.org/article/dfb85b4566c24718bd1f46e64f621960
Autor:
Ruiying Zhao, Lianying Guo, Bo Zhang, Jikai Zhao, Chan Xiang, Shengnan Chen, Jinchen Shao, Lei Zhu, Min Ye, Yuchen Han
Publikováno v:
The Journal of Pathology: Clinical Research, Vol 8, Iss 6, Pp 538-549 (2022)
Abstract This study aimed to present a comprehensive assessment of anaplastic lymphoma kinase (ALK) rearrangements evaluated by DNA/RNA‐based next‐generation sequencing (NGS) and Ventana immunohistochemistry (IHC) in patients with non‐small‐c
Externí odkaz:
https://doaj.org/article/3f651fa0561242a1aec8f72af8ba66c9
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.